QUESTIONSConference on Vaccine Research and Development
Venue: BSG Conference Centre
Location: London, London, United Kingdom
| Event Date/Time: Dec 07, 2009 | End Date/Time: Dec 08, 2009 |
Report as SpamDescription
http://www.bharatbook.com/Market-Research-Reports/Conference-on-Vaccine-Research-and-Development-.html
Background Info
Key Speakers
• Eric Claessens, Director of Bulk Technologies, GlaxoSmithKline Biologicals
• David McIntosh, Medical Director, Vaccines and Infectious Diseases, Wyeth
• Guido Grandi, Senior Project Leader, Novartis Vaccines and Diagnostics
• Jon H. Heinrichs, Senior Research Fellow, Vaccine Basic Research, Merck Research Laboratories
• James Merson, Vice President and Chief Scientific Officer, Vaccines Research Unit, Pfizer
• Alexander von Gabain, Chief Scientific Officer, Intercell
• Barry Buckland, Chief Executive Officer, BiologicB
• Andrew Baum, Managing Director Equity Research, Morgan Stanley
• Hélène Pora, Director, Vaccine Application Development, Pall Life Sciences
• Raf Lemmens, Global Fast Trak Leader, GE Healthcare Life Sciences
• Othmar Engelhardt, Principal Scientist, National Institute for Biological Standards and Control
• Jacqui Shea, General Manager, Oxford-Emergent Tuberculosis Consortium
• Pete Gagnon, Chief Scientific Officer, Validated Biosystems
• Bernd Eisele, Chief Executive Officer, Vakzine Projekt Management
• John Savopulos, Director, VacZine Analytics
• David Kirke, Associate Director, ERA Consulting
We stand poised for the second golden era of vaccines, born of new advances in fields from recombinant molecular biology, to mass spectrometry, and bioinformatics1. Allied with new advances in formulation and process development, the global market will see growth of over 300% between 2009and 20231,2.
With more targets, more investment and more opportunity than ever, vaccinology has become one of the most dynamic fields in biomedicine today. Progress in reverse vaccinology, immuno-informatics and disposable technologies are revolutionising R&D for infectious disease, paediatric and cancer therapies.
And, as demonstrated by Prevnar, Infanrix and Gardasil, the blockbuster model, far from being obsolete, is alive and kicking in an arena historically characterised by low margins.
The rise of developing economies and new markets in the Asia-Pacific regions are augmenting the financial promise shown by new paediatric and adult therapies, pointing to a bright future ahead.
By attending Vaccine Research & Development conference, you will benefit from distilled, market-focussed intelligence on the future for this exciting sector, from outstanding speakers in key areas including:
• Economic analysis of future trends including opportunities, drivers and challenges
• The R&D pipeline: future impact of new technologies
• How reverse vaccinology produced the H1N1 vaccine
• Progress towards a paediatric and adult 13 valent pneumococcal vaccine
• Surface proteome analysis as a fast-track for development of a GAS vaccine
• Clinical results for a new subunit booster vaccine for tuberculosis
• Development of a recombinant booster for prostate cancer
• New needle-free delivery methods
• Implementation of disposable technology in manufacturing
• Revisiting old tools in vaccine development
• MDCK cell-based based production methods and scale-up design considerations in bio-pharmaceutical manufacturing
• Purification of virus particles and DNA plasmids with monoliths
• The role of neutralising and monoclonal antibodies
• Collaborative partnering with lesser-developed countries
• BRIC countries in vaccine production
Day 1
Day One, Monday 7th December 2009
09:30 Registration and refreshments
10:00 Opening address from the chair
James Merson
Vice President and Chief Scientific Officer, Vaccines Research Unit
Pfizer
10:10 The global vaccine technology market: opportunities, drivers and challenges
• Drivers impacting industry investment in vaccines
• Factors increasing demand for advanced vaccine analytics
• Prospects for growth and strategic directions
Andrew Baum
Managing Director, Equity Research
Morgan Stanley
10:50 The vaccine R&D pipeline: future impact of new technologies
• Dynamics of vaccine market
• R&D pipeline – focus on emerging technologies
• Which companies are pursuing new vaccine technologies?
• Opportunities and challenges of new vaccine technologies
John Savopulos
Director
VacZine Analytics
11:30 Morning refreshments
11:50 Genomics in the discovery and design of novel vaccines for bacterial pathogens
• Use of genomics to identify vaccine targets for microbial pathogens
• Characterization of vaccine antigens using genomic tools
• Validation of vaccine targets in relevant model systems
Jon H. Heinrichs
Senior Research Fellow, Vaccine Basic Research
Merck Research Laboratories
12:30 Case study: Surface proteome analysis as a fast-track to vaccine discovery
• Stripping away cell-surface proteins
• Mass-spectrometry and in silico surfome analysis
• Identification and validation of new targets for group A Streptococcus
Guido Grandi
Senior Project Leader
Novartis Vaccines and Diagnostics
13:10 Networking lunch
14:30 Progress towards a paediatric and adult 13 valent pneumococcal vaccine
• Success of pneumococcal conjugate vaccine
• Changing epidemiology of pneumococcal infection
• Immunological considerations and correlates
• Development of new pneumococcal vaccines
David McIntosh
Medical Director for Vaccines and Infectious Diseases
Wyeth
15:10 Vaccine purification with monoliths
• How monoliths relate to porous particle and membrane-based media
• How monoliths support 10-100 times greater productivity than traditional media
• Examples from purification of virus particles and DNA plasmids
Pete Gagnon
Chief Scientific Officer
Validated Biosystems
15:50 Afternoon refreshments
16:10 Cell-based influenza vaccine process development and analysis: lessons learnt
• Analytical challenges in process development
• Approaches to purifying multiple strains
• Considerations on the use of single-use vs. conventional purification technology
Raf Lemmens
Global Fast Trak Leader
GE Healthcare Life Sciences
16:50 Implementation of disposable technology in vaccine manufacturing
• Where disposable technology is applicable in vaccine processing
• Why is it attractive in vaccine manufacturing
• Some examples of application including timelines
• Validation aspects
• Conclusion with references to the impact on the environment
Hélène Pora
Director, Vaccine Application Development
Pall Life Sciences
17:30 Closing remarks from the chair
17:40 Networking drinks
Day 2
Day Two, Tuesday 8th December 2009
09:30 Registration and refreshments
10:00 Opening address from the chair
Eric Claessens
Director, Bulk Technologies
GlaxoSmithKline Biologicals
10:10 Collaborative vaccine partnering
• Growing importance of vaccine manufacturers in developing countries to ensure access to vaccines
• Initiatives to achieve more equitable vaccine manufacturing capacity at the global level
• Technology transfer collaborations
Barry Buckland
Chief Executive Officer, BiologicB
Formerly Vice-President, Bioprocess R&D
Merck Research Laboratories
10:50 China- the future hub for influenza production
• Looking at innovation, speed, quality and competitive costs
• Resolving supply chain issues
• Discussing the evaluation process
11:30 Morning refreshments
11:50 Emergency preparedness and response: where the public sector can play a role in developing interventions such as vaccines
• What role can vaccines play in preparedness and response?
• Reality of developing and manufacturing new vaccines to meet the challenge
• HPA translational research model
• A strategic vaccine concept
Steve Chatfield
Director, Centre for Emergency Preparedness and Response
Health Protection Agency
12:30 Case study: Developing the first vaccine virus for pandemic H1N1
• Reverse vaccinology for H1N1
• Isolation, testing and validation
• Production and distribution
Othmar Engelhardt
Principal Scientist
National Institute for Biological Standards and Control
13:10 Networking lunch
14:30 From a needle-free ETEC vaccine to a vaccine enhancement patch
• Epidermal skin, an optimal site for vaccine delivery
• A patch delivering ETEC vaccine based on LT toxin
• LT toxin functions as a vaccine enhancement tool when delivered via the skin
Alexander von Gabain
Chief Scientific Officer
Intercell
15:10 Case study: MVA85A- a new subunit booster vaccine for tuberculosis
Jacqui Shea
General Manager
Oxford-Emergent Tuberculosis Consortium
15:50 Afternoon refreshments
16:10 Development of an rBCG adjuvanted allogeneic vaccine against prostate cancer
• Development of a GM live vaccine (VPM1002) against tuberculosis: results from phase I trials
• Development of an allogeneic therapeutic vaccine (VPM4001) against prostate cancer: phase I/II results
• A boosting/adjuvant strategy: VPM4001 + VPM1002 to increase the Th1 immune response against prostate cancer
Bernd Eisele
Chief Executive Officer
Vakzine Projekt Management
16:50 Current regulatory concerns regarding long-term safety of vaccines
• Current safety challenges
• Balancing purity of the antigen and adjuvant with adequate antigenicity
• Models for pre-clinical testing, and clinical trials demonstrating adequate safety
David Kirke
Associate Director
ERA Consulting
17:30 Chair’s closing remarks
17:40 End of conference
Background Info
Key Speakers
• Eric Claessens, Director of Bulk Technologies, GlaxoSmithKline Biologicals
• David McIntosh, Medical Director, Vaccines and Infectious Diseases, Wyeth
• Guido Grandi, Senior Project Leader, Novartis Vaccines and Diagnostics
• Jon H. Heinrichs, Senior Research Fellow, Vaccine Basic Research, Merck Research Laboratories
• James Merson, Vice President and Chief Scientific Officer, Vaccines Research Unit, Pfizer
• Alexander von Gabain, Chief Scientific Officer, Intercell
• Barry Buckland, Chief Executive Officer, BiologicB
• Andrew Baum, Managing Director Equity Research, Morgan Stanley
• Hélène Pora, Director, Vaccine Application Development, Pall Life Sciences
• Raf Lemmens, Global Fast Trak Leader, GE Healthcare Life Sciences
• Othmar Engelhardt, Principal Scientist, National Institute for Biological Standards and Control
• Jacqui Shea, General Manager, Oxford-Emergent Tuberculosis Consortium
• Pete Gagnon, Chief Scientific Officer, Validated Biosystems
• Bernd Eisele, Chief Executive Officer, Vakzine Projekt Management
• John Savopulos, Director, VacZine Analytics
• David Kirke, Associate Director, ERA Consulting
We stand poised for the second golden era of vaccines, born of new advances in fields from recombinant molecular biology, to mass spectrometry, and bioinformatics1. Allied with new advances in formulation and process development, the global market will see growth of over 300% between 2009and 20231,2.
With more targets, more investment and more opportunity than ever, vaccinology has become one of the most dynamic fields in biomedicine today. Progress in reverse vaccinology, immuno-informatics and disposable technologies are revolutionising R&D for infectious disease, paediatric and cancer therapies.
And, as demonstrated by Prevnar, Infanrix and Gardasil, the blockbuster model, far from being obsolete, is alive and kicking in an arena historically characterised by low margins.
The rise of developing economies and new markets in the Asia-Pacific regions are augmenting the financial promise shown by new paediatric and adult therapies, pointing to a bright future ahead.
By attending Vaccine Research & Development conference, you will benefit from distilled, market-focussed intelligence on the future for this exciting sector, from outstanding speakers in key areas including:
• Economic analysis of future trends including opportunities, drivers and challenges
• The R&D pipeline: future impact of new technologies
• How reverse vaccinology produced the H1N1 vaccine
• Progress towards a paediatric and adult 13 valent pneumococcal vaccine
• Surface proteome analysis as a fast-track for development of a GAS vaccine
• Clinical results for a new subunit booster vaccine for tuberculosis
• Development of a recombinant booster for prostate cancer
• New needle-free delivery methods
• Implementation of disposable technology in manufacturing
• Revisiting old tools in vaccine development
• MDCK cell-based based production methods and scale-up design considerations in bio-pharmaceutical manufacturing
• Purification of virus particles and DNA plasmids with monoliths
• The role of neutralising and monoclonal antibodies
• Collaborative partnering with lesser-developed countries
• BRIC countries in vaccine production
Day 1
Day One, Monday 7th December 2009
09:30 Registration and refreshments
10:00 Opening address from the chair
James Merson
Vice President and Chief Scientific Officer, Vaccines Research Unit
Pfizer
10:10 The global vaccine technology market: opportunities, drivers and challenges
• Drivers impacting industry investment in vaccines
• Factors increasing demand for advanced vaccine analytics
• Prospects for growth and strategic directions
Andrew Baum
Managing Director, Equity Research
Morgan Stanley
10:50 The vaccine R&D pipeline: future impact of new technologies
• Dynamics of vaccine market
• R&D pipeline – focus on emerging technologies
• Which companies are pursuing new vaccine technologies?
• Opportunities and challenges of new vaccine technologies
John Savopulos
Director
VacZine Analytics
11:30 Morning refreshments
11:50 Genomics in the discovery and design of novel vaccines for bacterial pathogens
• Use of genomics to identify vaccine targets for microbial pathogens
• Characterization of vaccine antigens using genomic tools
• Validation of vaccine targets in relevant model systems
Jon H. Heinrichs
Senior Research Fellow, Vaccine Basic Research
Merck Research Laboratories
12:30 Case study: Surface proteome analysis as a fast-track to vaccine discovery
• Stripping away cell-surface proteins
• Mass-spectrometry and in silico surfome analysis
• Identification and validation of new targets for group A Streptococcus
Guido Grandi
Senior Project Leader
Novartis Vaccines and Diagnostics
13:10 Networking lunch
14:30 Progress towards a paediatric and adult 13 valent pneumococcal vaccine
• Success of pneumococcal conjugate vaccine
• Changing epidemiology of pneumococcal infection
• Immunological considerations and correlates
• Development of new pneumococcal vaccines
David McIntosh
Medical Director for Vaccines and Infectious Diseases
Wyeth
15:10 Vaccine purification with monoliths
• How monoliths relate to porous particle and membrane-based media
• How monoliths support 10-100 times greater productivity than traditional media
• Examples from purification of virus particles and DNA plasmids
Pete Gagnon
Chief Scientific Officer
Validated Biosystems
15:50 Afternoon refreshments
16:10 Cell-based influenza vaccine process development and analysis: lessons learnt
• Analytical challenges in process development
• Approaches to purifying multiple strains
• Considerations on the use of single-use vs. conventional purification technology
Raf Lemmens
Global Fast Trak Leader
GE Healthcare Life Sciences
16:50 Implementation of disposable technology in vaccine manufacturing
• Where disposable technology is applicable in vaccine processing
• Why is it attractive in vaccine manufacturing
• Some examples of application including timelines
• Validation aspects
• Conclusion with references to the impact on the environment
Hélène Pora
Director, Vaccine Application Development
Pall Life Sciences
17:30 Closing remarks from the chair
17:40 Networking drinks
Day 2
Day Two, Tuesday 8th December 2009
09:30 Registration and refreshments
10:00 Opening address from the chair
Eric Claessens
Director, Bulk Technologies
GlaxoSmithKline Biologicals
10:10 Collaborative vaccine partnering
• Growing importance of vaccine manufacturers in developing countries to ensure access to vaccines
• Initiatives to achieve more equitable vaccine manufacturing capacity at the global level
• Technology transfer collaborations
Barry Buckland
Chief Executive Officer, BiologicB
Formerly Vice-President, Bioprocess R&D
Merck Research Laboratories
10:50 China- the future hub for influenza production
• Looking at innovation, speed, quality and competitive costs
• Resolving supply chain issues
• Discussing the evaluation process
11:30 Morning refreshments
11:50 Emergency preparedness and response: where the public sector can play a role in developing interventions such as vaccines
• What role can vaccines play in preparedness and response?
• Reality of developing and manufacturing new vaccines to meet the challenge
• HPA translational research model
• A strategic vaccine concept
Steve Chatfield
Director, Centre for Emergency Preparedness and Response
Health Protection Agency
12:30 Case study: Developing the first vaccine virus for pandemic H1N1
• Reverse vaccinology for H1N1
• Isolation, testing and validation
• Production and distribution
Othmar Engelhardt
Principal Scientist
National Institute for Biological Standards and Control
13:10 Networking lunch
14:30 From a needle-free ETEC vaccine to a vaccine enhancement patch
• Epidermal skin, an optimal site for vaccine delivery
• A patch delivering ETEC vaccine based on LT toxin
• LT toxin functions as a vaccine enhancement tool when delivered via the skin
Alexander von Gabain
Chief Scientific Officer
Intercell
15:10 Case study: MVA85A- a new subunit booster vaccine for tuberculosis
Jacqui Shea
General Manager
Oxford-Emergent Tuberculosis Consortium
15:50 Afternoon refreshments
16:10 Development of an rBCG adjuvanted allogeneic vaccine against prostate cancer
• Development of a GM live vaccine (VPM1002) against tuberculosis: results from phase I trials
• Development of an allogeneic therapeutic vaccine (VPM4001) against prostate cancer: phase I/II results
• A boosting/adjuvant strategy: VPM4001 + VPM1002 to increase the Th1 immune response against prostate cancer
Bernd Eisele
Chief Executive Officer
Vakzine Projekt Management
16:50 Current regulatory concerns regarding long-term safety of vaccines
• Current safety challenges
• Balancing purity of the antigen and adjuvant with adequate antigenicity
• Models for pre-clinical testing, and clinical trials demonstrating adequate safety
David Kirke
Associate Director
ERA Consulting
17:30 Chair’s closing remarks
17:40 End of conference
Venue
Restrictions
Invitation Only
